Brief: Revive announces completion of rights offering
20/06/2016 13:00
June 20 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Revive announces completion of rights offering for gross
proceeds of $844,693 to fund the clinical development of
Bucillamine for the treatment of Cystinuria
Source text for Eikon: ID:nCCNbWYNHy
Further company coverage: RVV.V
((Bengaluru Newsroom: +1-646-223-8780))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure